Study title:
Longo-D-L, Russo-A, Duffey-P-L, Hubbard-S-M, Glatstein-E, Hill-J-B,
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, {J-Clin-Oncol}, Feb 1991, vol. 9, no. 2, p. 227-35, ISSN: 0732-183X.Longo-D-L, Russo-A, Duffey-P-L, Hubbard-S-M, Glatstein-E, Hill-J-B,
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, {J-Clin-Oncol...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|